All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Artificial intelligence
    • Coronavirus
    • Diagnosing and tracking COVID-19
    • Drugs to Watch 2020
    • The next pandemic
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, September 21, 2021
See today's BioWorld MedTech
Home » Tali Digital out-licenses digital therapeutic for ADHD to Akili in deal worth A$51 million
X
/images/Cortellis_Flagship_Logo_TM_RGB_Color.png

Upgrade your daily dose of biopharma and medtech news

Subscribe to BioWorld™ news services

See subscription options
To read the full story, subscribe or sign in.

Tali Digital out-licenses digital therapeutic for ADHD to Akili in deal worth A$51 million

Aug. 20, 2021
By Tamra Sami
No Comments
PERTH, Australia – Tali Digital Ltd. inked a licensing deal worth A$51 million (US$37.5 million) for its new digital therapeutic that could be the first line in early intervention to treat the underlying conditions of attention deficit disorders. Akili Interactive Labs Inc. will hold an ongoing license to Tali’s technology to become the exclusive commercialization partner for all pediatric cognition products in the U.S.
BioWorld MedTech Deals and M&A Neurology/Psychiatric Digital health Asia-Pacific Australia

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for September 20.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech's briefs for Sept. 20.
  • Coronavirus vaccine illustration

    ACIP unanimously backs Pfizer/Biontech vaccine; booster data in October?

    BioWorld
    The CDC’s Advisory Committee on Immunization Practices (ACIP) heard a safety update on COVID-19 vaccines, took up the matter of booster shots, and voted on...
  • FDA icons

    Class effect is all JAKed up as applications remain pending at FDA

    BioWorld
    Pfizer Inc. reported on Aug. 30, 2021, that its JAK inhibitor, abrocitinib, beat Dupixent (dupilumab, Regeneron Pharmaceuticals Inc./Sanofi SA) in a head-to-head...
  • New Nrx COVID-19 data show improved lung function

    BioWorld
    New data from Nrx Pharmaceuticals Inc.’s phase IIb/III trial for treating acute respiratory failure due to critical COVID-19 showed that Zyesami (aviptadil)...
black cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • About
    • Archives
    • Today's news
    • Search BioWorld Science
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing